Work

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

Year: 2006

Type: article

Study design: Clinical Trial

Source: Breast Cancer Research and Treatment

DOI: 10.1007/s10549-006-9307-8

Authors: P. Kelly Marcom, Claudine Isaacs, Lyndsay Harris, Zee Wang Wong, Aruna Kommarreddy, Nellie Novielli, Gretchen Mann, Yu Tao, Matthew J. Ellis

Institutions: Duke University, Washington University in St. Louis, Duke Medical Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1996920020

FWCI: 9.453

Cites: 18

Cited by: 156

Related to: 10